 Disease-Free Survival
"Disease-Free Survival" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Period after successful treatment in which there is no appearance of the symptoms or effects of the disease.
| Descriptor ID |
D018572
|
| MeSH Number(s) |
E01.789.200 E05.318.740.998.300 N05.715.360.750.795.300 N06.850.520.830.998.300
|
| Concept/Terms |
Disease-Free Survival- Disease-Free Survival
- Disease Free Survival
- Event-Free Survival
- Event Free Survival
- Event-Free Survivals
- Survival, Event-Free
- Survivals, Event-Free
- Survival, Disease-Free
- Disease-Free Survivals
- Survival, Disease Free
- Survivals, Disease-Free
Progression-Free Survival- Progression-Free Survival
- Progression Free Survival
- Progression-Free Survivals
- Survival, Progression-Free
- Survivals, Progression-Free
|
Below are MeSH descriptors whose meaning is more general than "Disease-Free Survival".
Below are MeSH descriptors whose meaning is more specific than "Disease-Free Survival".
This graph shows the total number of publications written about "Disease-Free Survival" by people in this website by year, and whether "Disease-Free Survival" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 0 | 5 | 5 | | 1997 | 0 | 7 | 7 | | 1998 | 0 | 10 | 10 | | 1999 | 0 | 6 | 6 | | 2000 | 0 | 6 | 6 | | 2001 | 0 | 9 | 9 | | 2002 | 0 | 11 | 11 | | 2003 | 0 | 5 | 5 | | 2004 | 0 | 7 | 7 | | 2005 | 0 | 9 | 9 | | 2006 | 0 | 8 | 8 | | 2007 | 0 | 16 | 16 | | 2008 | 0 | 16 | 16 | | 2009 | 0 | 14 | 14 | | 2010 | 0 | 29 | 29 | | 2011 | 0 | 18 | 18 | | 2012 | 0 | 31 | 31 | | 2013 | 0 | 39 | 39 | | 2014 | 0 | 36 | 36 | | 2015 | 0 | 45 | 45 | | 2016 | 0 | 43 | 43 | | 2017 | 0 | 61 | 61 | | 2018 | 0 | 34 | 34 | | 2019 | 0 | 37 | 37 | | 2020 | 0 | 22 | 22 | | 2021 | 0 | 12 | 12 | | 2022 | 0 | 10 | 10 | | 2023 | 0 | 8 | 8 | | 2024 | 0 | 6 | 6 | | 2025 | 0 | 11 | 11 | | 2026 | 0 | 2 | 2 |
To return to the timeline, click here.
Below are the most recent publications written about "Disease-Free Survival" by people in Profiles.
-
Sinicrope FA, Ou FS, Arnold D, Peters WR, Behrens RJ, Lieu CH, Matin K, Cohen DJ, Potter SL, Nixon AB, Kottschade LA, Kathol E, Frankel WL, Shergill A, Hsu D, Reinacher-Schick A, Mehan P, Gold PJ, Khalil MF, Zemla T, Gatten C, O'Reilly EM, Meyerhardt JA. Atezolizumab plus FOLFOX for Stage III Mismatch Repair-Deficient Colon Cancer. N Engl J Med. 2026 Mar 26; 394(12):1155-1166.
-
Pathak KA, Agarwal A, Klemm N, Kotecha P, Sayed S, Leslie WD. Selective Use of Radioiodine Therapy in Differentiated Thyroid Carcinoma: A Population-Based Cohort Study. Thyroid. 2026 Mar; 36(3):345-349.
-
Hilty Chu BK, Dhimal T, Boyer M, Loria A, Lai SH, Cai X, Li Y, Cupertino P, George V, Aquina CT, Donahue C, Vogel JD, Fleming FJ. A Clinical Primer for Defining Time Zero in Rectal Cancer Studies of Nonoperative Management: Implications for Survival and Local Regrowth. Ann Surg Oncol. 2026 Mar; 33(3):1927-1934.
-
Chávez-Villa M, Sasaki K, Nakayama T, Byrne MM, Jimenez-Soto C, Ruffolo LI, Endo Y, Dokus MK, Bekki Y, Qadan M, Tomiyama K, Roberts JP, Pomfret E, Wall A, Hernández-Alejandro R. Optimizing liver transplant outcomes for colorectal liver metastases in the United States. Liver Transpl. 2026 Apr 01; 32(4):508-517.
-
Matsuo K, Enserro DM, Wright JD, Roman LD, Powell MA, Miller DS, Nagel CI, Thaker PH, Mannel RS, Stuckey AR, Guntupalli SR, Sukumvanich P, Geller MA, Vargas R, Konecny GE, Warshal DP, Tewari KS, Spirtos NM, Pothuri B, Creasman WT, Mutch DG. Prospective assessment of prognostic significance of malignant peritoneal cytology in endometrial cancer: An NRG Oncology / Gynecologic Oncology Group study on GOG-210 protocol. Gynecol Oncol. 2025 Oct; 201:184-194.
-
Akabane M, Kawashima J, Woldesenbet S, Cauchy F, Aucejo F, Popescu I, Kitago M, Martel G, Ratti F, Aldrighetti L, Poultsides GA, Imaoka Y, Ruzzenente A, Endo I, Gleisner A, Marques HP, Lam V, Hugh T, Bhimani N, Shen F, Pawlik TM. International validation of a natural-killer-cell-based model to predict recurrence-free survival in hepatocellular carcinoma. HPB (Oxford). 2025 Oct; 27(10):1259-1269.
-
Akabane M, Kawashima J, Woldesenbet S, Lee GR, Cauchy F, Aucejo F, Popescu I, Kitago M, Martel G, Ratti F, Aldrighetti L, Poultsides GA, Imaoka Y, Ruzzenente A, Endo I, Gleisner A, Marques HP, Lam V, Hugh T, Bhimani N, Shen F, Pawlik TM. Distinct patterns of late recurrence in long-term hepatocellular carcinoma survivors. J Gastrointest Surg. 2025 09; 29(9):102135.
-
Akabane M, Kawashima J, Altaf A, Woldesenbet S, Cauchy F, Aucejo F, Popescu I, Kitago M, Martel G, Ratti F, Aldrighetti L, Poultsides GA, Imaoka Y, Ruzzenente A, Endo I, Gleisner A, Marques HP, Oliveira S, Balaia J, Lam V, Hugh T, Bhimani N, Shen F, Pawlik TM. Unraveling the obesity paradox in hepatocellular carcinoma: relative role of elevated body mass index on detrimental effects of postoperative complications. HPB (Oxford). 2025 Aug; 27(8):1103-1112.
-
Akiki A, Jacobsson H, Nouairia G, Cornillet M, Björkström NK, Sparrelid E, Taflin H, Jansson H. External validation of plasma CSF1 as a preoperative prognostic marker in patients with resectable intrahepatic cholangiocarcinoma. Eur J Surg Oncol. 2025 Aug; 51(8):110123.
-
Guenther JM, Ward A, Martin BJ, Cripe M, Beard T, Wisco O, Sharma R, Leong SP, Essner R, Clark JI, Hamner J, Sickle-Santanello B, Yamamoto M. A Prospective, Multicenter Analysis of Recurrence-Free Survival After Sentinel Lymph Node Biopsy Decisions Influenced by the 31-GEP. Cancer Med. 2025 Apr; 14(7):e70839.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|